To review the role of anatomic endpoints in clinical trials for the study of nonexudative age-related macular degeneration (AMD) with an emphasis on a novel composite endpoint for the study of emerging therapies for intermediate AMD (iAMD).

To provide visual and anatomic outcomes for patients with retinal detachment (RD) in whom primary pneumatic retinopexy (PR) failed.

To examine the impact of topical corticosteroid use after the start of antiamoebic therapy (AAT) on the outcomes of Acanthamoeba keratitis (AK) therapy.

Medidur, an injectable insert that provides sustained release of flucinolone acetonide for 3 years, helps prevent recurrence of posterior uveitis.

This non-randomized clinical trial assessed the efficacy of 2% ibopamine, a topical drug that temporarily increases aqueous production, for diagnosing glaucoma.

Although primary congenital glaucoma (PCG) is a rare disease, it occurs worldwide. Surgery is the mainstay of treatment of PCG, with surgical success rates having improved dramatically over the past few decades to 70% to 80%.1 However, there are few reports of patient-reported outcomes in PCG.2,3 A diagnosis of a sight-threatening condition such as PCG in a newborn or very young child can have significant psychosocial implications for families, who may experience a range of emotions such as guilt, fear, sadness, anxiety, and grief.